Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX2 | P34913 | 1/20 | 0.59 |
| ▸ | GAA | P10253 | 2/20 | 0.51 |
| ▸ | NFKB1 | P19838 | 2/20 | 0.46 |
| ▸ | NFKB2 | Q00653 | 2/20 | 0.46 |
| ▸ | RELA | Q04206 | 2/20 | 0.46 |
| ▸ | BTK | Q06187 | 1/20 | 0.45 |
| ▸ | CTSK | P43235 | 2/20 | 0.42 |
| ▸ | KDM1A | O60341 | 1/20 | 0.40 |
| ▸ | MAOB | P27338 | 1/20 | 0.40 |
| ▸ | HPGDS | O60760 | 2/20 | 0.39 |
| ▸ | CA1 | P00915 | 1/20 | 0.39 |
| ▸ | CA2 | P00918 | 1/20 | 0.39 |
| ▸ | IDO1 | P14902 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.39 |
| ▸ | PIM1 | P11309 | 1/20 | 0.38 |
| ▸ | PIM3 | Q86V86 | 1/20 | 0.38 |
| ▸ | PIM2 | Q9P1W9 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3735359 | 1.00 | EPHX2 (0.59) | EPHX2GAANFKB1NFKB2RELA | |
| SCHEMBL15595143 | 1.00 | EPHX2 (0.59) | EPHX2GAANFKB1NFKB2RELA | |
| SCHEMBL26696840 | 0.86 | EPHX2 (0.52) | EPHX2GAANFKB1NFKB2RELA | |
| SCHEMBL24096964 | 0.86 | EPHX2 (0.52) | EPHX2GAANFKB1NFKB2RELA | |
| SCHEMBL382915 | 0.86 | EPHX2 (0.52) | EPHX2GAANFKB1NFKB2RELA | |
| SCHEMBL19968080 | 0.84 | GAA (0.49) | EPHX2GAANFKB1NFKB2RELA | |
| SCHEMBL4988935 | 0.84 | GAA (0.49) | EPHX2GAANFKB1NFKB2RELA | |
| SCHEMBL452060 | 0.83 | GAA (0.54) | EPHX2GAANFKB1NFKB2RELA | |
| SCHEMBL7097599 | 0.81 | BTK (0.51) | EPHX2GAANFKB1NFKB2RELA | |
| SCHEMBL8325782 | 0.81 | BTK (0.51) | EPHX2GAANFKB1NFKB2RELA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 32 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4714953-A1 | MELANOCORTIN 2-TYPE RECEPTOR ANTAGONIST | Scohia Pharma, Inc. (JP) | 2026-03-25 | — | — | EP | disclosed |
| WO-2025224262-A1 | COMBINATION THERAPIES COMPRISING A CDK2 DEGRADER AND A CDK4/6 INHIBITOR | MONTE ROSA THERAPEUTICS AG (CH) | 2025-10-30 | — | — | WO | disclosed |
| EP-4608816-A1 | COMPOUNDS THAT MEDIATE PROTEIN DEGRADATION AND METHODS OF USE THEREOF | Monte Rosa Therapeutics AG (CH) | 2025-09-03 | — | — | EP | disclosed |
| US-20250263395-A1 | COMPOUNDS THAT MEDIATE PROTEIN DEGRADATION AND METHODS OF USE THEREOF | MONTE ROSA THERAPEUTICS AG (CH) | 2025-08-21 | — | — | US | disclosed |
| US-12312336-B2 | Inhibitors of RAF kinases | Pierre Fabre Médicament (FR) | 2025-05-27 | — | — | US | disclosed |
| WO-2024237266-A1 | MELANOCORTIN 2-TYPE RECEPTOR ANTAGONIST | 株式会社スコヒアファーマ | 2024-11-21 | — | — | WO | disclosed |
| CN-118574834-A | Fused tetracyclic compounds, compositions and uses thereof | 泰博生物科技股份有限公司 | 2024-08-30 | — | — | CN | disclosed |
| US-20240140958-A1 | FUSED QUADRACYCLIC COMPOUNDS, COMPOSITIONS AND USES THEREOF | TABOMEDEX BIOSCIENCES INC (US) | 2024-05-02 | — | — | US | disclosed |
| WO-2024092039-A1 | COMPOUNDS THAT MEDIATE PROTEIN DEGRADATION AND METHODS OF USE THEREOF | MONTE ROSA THERAPEUTICS, INC. (US) | 2024-05-02 | — | — | WO | disclosed |
| EP-4126855-B1 | COMPOUNDS AND THEIR USE IN THE TREATMENT OF BACTERIAL INFECTIONS | HOFFMANN LA ROCHE (CH) | 2024-04-24 | — | — | EP | disclosed |
| EP-2857404-B1 | IMIDAZO[1,2-b]PYRIDAZINE DERIVATIVES AS KINASE INHIBITORS | DAIICHI SANKYO CO LTD (JP) | 2017-08-23 | — | — | EP | disclosed |
| US-20160046639-A1 | IMIDAZO[1,2-b]PYRIDAZINE DERIVATIVES AS KINASE INHIBITORS | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2016-02-18 | — | — | US | disclosed |
| US-9187489-B2 | Imidazo[1,2-b]pyridazine derivatives as kinase inhibitors | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2015-11-17 | — | — | US | disclosed |
| EP-2857404-A1 | IMIDAZO[1,2-b]PYRIDAZINE DERIVATIVE AS KINASE INHIBITOR | Daiichi Sankyo Co., Ltd. (JP) | 2015-04-08 | — | — | EP | disclosed |
| US-20150051190-A1 | IMIDAZO[1,2-b]PYRIDAZINE DERIVATIVES AS KINASE INHIBITORS | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2015-02-19 | — | — | US | disclosed |
| US-8952010-B2 | Amino group-containing pyrrolidinone derivative | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2015-02-10 | — | — | US | disclosed |
| US-8952010-B2 | Amino group-containing pyrrolidinone derivative | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2015-02-10 | — | — | US | disclosed |
| US-20140187542-A1 | AMINO GROUP-CONTAINING PYRROLIDINONE DERIVATIVE | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2014-07-03 | — | — | US | disclosed |
| US-20140187542-A1 | AMINO GROUP-CONTAINING PYRROLIDINONE DERIVATIVE | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2014-07-03 | — | — | US | disclosed |
| WO-2004022536-A1 | NEW HETEROCYCLIC AMIDE COMPOUNDS USEFUL FOR THE TREATMENT OF INFLAMMATORY AND ALLERGIC DISORDERS: PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | GLENMARK PHARMACEUTICALS LIMITED (US) | 2004-03-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150051190-A1 | IMIDAZO[1,2-b]PYRIDAZINE DERIVATIVES AS KINASE INHIBITORS | ROS1, JAK1, ERBB2 | EPHX2 4503/4885GAA 2515/4885NFKB1 1116/4885 |
| US-20140187542-A1 | AMINO GROUP-CONTAINING PYRROLIDINONE DERIVATIVE | AR, RCC2, NR3C2 | EPHX2 4760/4885GAA 4800/4885NFKB1 2831/4885 |
| US-20160046639-A1 | IMIDAZO[1,2-b]PYRIDAZINE DERIVATIVES AS KINASE INHIBITORS | ROS1, JAK1, ERBB2 | EPHX2 4503/4885GAA 2515/4885NFKB1 1116/4885 |
| US-20250263395-A1 | COMPOUNDS THAT MEDIATE PROTEIN DEGRADATION AND METHODS OF USE THEREOF | CDK2, SKP2, CDK1 | EPHX2 3607/4885GAA 2291/4885NFKB1 1006/4885 |
| US-20240140958-A1 | FUSED QUADRACYCLIC COMPOUNDS, COMPOSITIONS AND USES THEREOF | MKNK2, CYP2J2, PTGS2 | EPHX2 284/4885GAA 2044/4885NFKB1 2110/4885 |
| US-12312336-B2 | Inhibitors of RAF kinases | BRAF, RAF1, ARAF | EPHX2 1926/4885GAA 1754/4885NFKB1 1350/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.